Clinical and Genetic Analysis of 63 Families Demonstrating Early and Advanced Characteristic Fundus As the Signature of CRB1 Mutations.

Yingwei Wang,Wenmin Sun,Xueshan Xiao,Shiqiang Li,Xiaoyun Jia,Panfeng Wang,Qingjiong Zhang
DOI: https://doi.org/10.1016/j.ajo.2020.10.006
IF: 5.488
2021-01-01
American Journal of Ophthalmology
Abstract:PURPOSE: To reveal the characteristics of ocular changes in patients with biallelic CRB1 mutations. DESIGN: Comparative exome sequencing and retrospective case series on clinical data. METHODS: Seventy-four patients from 63 families with biallelic potential pathogenic variants in CRB1 were selected from our in-house exome sequencing. The clinical data were reviewed and evaluated in detail, including bestcorrected visual acuity, fundus photography, optical coherence tomography (OCT), and electroretinogram (ERG). RESULTS: Biallelic CRB1 variants, involving 45 variants including 23 novel, were identified in 40 novel families based on exome sequencing. Analyzing clinical data of the 74 individuals from 63 families revealed the following CRB1-associated phenotypes: (1) early-onset reduced visual acuity with congenital nystagmus; (2) 2 types of characteristic retinal changes including yellowish geographic macular degeneration (YMD) or nummular pigment deposits (NPD) at posterior retina with bone-spicule pigmentation at midperipheral retina; (3) undetectable rod and cone responses on ERG; (4) cystoid macular edema or macular atrophy on OCT. YMD and NPD are unique and CRB1-associated. Long-term follow-up examination as well as age- and variantdependent phenotypic analysis suggested YMD is the early fundus change that would gradually progress to NPD. CONCLUSIONS: YMD and NPD are 2 major characteristic CRB1-associated fundus changes and the former one will advance to the latter with age. Recognizing such characteristic signs associated with biallelic CRB1 variants may be of value in areas without widespread access to genetic testing where a more targeted approach is needed and might be biomarkers for evaluation of effects for future intervention. ((C) 2020 The Author(s). Published by Elsevier Inc.
What problem does this paper attempt to address?